US-based Mylan's Canadian subsidiary Mylan Pharmaceuticals has launched three generic anti-retroviral (ARV) medicines for the treatment of HIV for certain patients in Canada.
Go deeper with GlobalData
The company has received final approval from Health Canada for the three products.
The treatments include emtricitabine / tenofovir disoproxil fumarate at 200mg / 300mg, which is a generic alternative to truvada; efavirenz / emtricitabine / tenofovir disoproxil fumarate at 600mg, 200mg and 300mg, a generic alternative to Atripla; and tenofovir disoproxil at 300mg, a generic alternative to Viread.
Mylan chief commercial officer Tony Mauro said: “Mylan has a strong and sustained commitment to expanding access to treatment for HIV / AIDS and other diseases around the world, and today marks another milestone in those efforts.
“More than 40% of people worldwide being treated for HIV / AIDS with an anti-retroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada.”
Mylan has invested $250m in extending its ARV manufacturing capacity to date, thereby allowing the company four billion ARV tablets and capsules each year.
Mylan-emtricitabine / tenofovir disoproxil fumarate at 200mg / 300mg has been indicated in combination with other ARV agents for the treatment of adult patients with HIV-1 infection.
Mylan-efavirenz / emtricitabine / tenofovir disoproxil fumarate at 600mg, 200mg, and 300mg can be used alone as a complete regimen or in combination with other ARV agents for the treatment of HIV-1 infection in adults.
Mylan-tenofovir disoproxil at 300mg can be used in combination with other ARV agents to treat HIV-1 infection in patients aged 12 and older, in addition to the treatment of chronic hepatitis B infection in adults.
Image: Scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocyte. Photo: courtesy of C. Goldsmith.
